Clinical trials are moving out of hospitals and research centers and into people’s living rooms. Home visits, remote assessments, and community-based care are no longer a workaround for hard-to-reach patients. They are becoming a core part of how modern trials are designed. And with the update to ICH E6(R3), the global standard for Good Clinical Practice, that shift is now being formally recognized at the regulatory level.
For Sponsors, CROs, and patients alike, this is good news. For mobile nursing providers like WEP Clinical, it’s a validation of everything we have built our model around: bringing high-quality clinical care directly to the patient, wherever they are.
Why This Matters Now
Decentralized clinical trials (DCTs) have grown steadily over the past several years, driven by a simple insight: requiring patients to travel repeatedly to a study site is one of the biggest barriers to trial participation and retention. Home visits, local healthcare provider networks, and remote data collection solve that problem. But, until recently, the regulatory framework had not fully caught up with the practice.
That is changing. The newly restructured ICH E6(R3) guideline now includes a dedicated section – Annex 2 – specifically addressing trial activities that happen outside the traditional investigator site. In doing so, it treats home visits, remote assessments, and mobile nursing not as a supporting service bolted onto a “real” trial, but as a legitimate and expected component of modern trial conduct.
What This Means for Patients
For patients, the benefits of home-based trial support are significant and well established:
- Reduced burden. No repeated travel to a distant study site, less time away from work and family, and lower logistical and financial strain.
- Broader access. Patients in rural areas, those with mobility limitations, and those managing chronic or serious illness can participate in research that would otherwise be out of reach.
- Better continuity of care. A consistent, trusted nurse visiting the home builds rapport and can catch changes in a patient’s condition early.
- Higher retention. Patients who don’t have to fight through traffic or take a day off work to attend a visit are more likely to stay enrolled through the full course of a study.
Put simply: trials that come to the patient are trials patients are more likely to stay in – and that means better data, faster enrollment, and more successful studies overall.
Why Sponsors Are Paying Attention
For Sponsors and CROs, the case for incorporating home nursing into trial design has moved beyond “nice to have” convenience. Regulatory clarity now exists for how these activities fit within a compliant trial framework – and that changes the calculus.
Some of the biggest advantages Sponsors are recognizing include:
- Faster, more diverse enrollment. Removing the site-visit barrier opens participation to a wider and more representative patient population.
- Improved protocol adherence. In-home assessments and monitoring can catch issues – like missed doses, adverse events, deteriorating vitals – earlier than a monthly site visit ever could.
- Stronger retention through the life of the study. Fewer dropouts mean cleaner datasets and lower overall trial costs.
- A defined path to compliance. Where DCT models once operated in a regulatory gray area, Annex 2 now provides clear expectations for how decentralized activities should be governed, documented, and overseen – giving Sponsors confidence that home-based components can hold up under inspection.
Raising the Bar for Mobile Nursing Providers
The flip side of this recognition is higher expectations. Annex 2 makes clear that decentralized activities are still part of the clinical trial and remain under the oversight of the investigator and Sponsor – no matter how far from the traditional site they take place. The further the activity moves from the site, the more important it becomes to demonstrate strong governance, clear escalation pathways, and reliable data.
That means mobile nursing organizations are increasingly being evaluated not just on nurse availability and clinical skill, but on their ability to operate as a true extension of the Sponsor’s quality and compliance infrastructure – with documented training, clear delegation of duties, defined escalation procedures for adverse events, and data capture processes that can withstand regulatory scrutiny.
This is exactly the standard WEP Clinical has been built to meet. Our approach to home-based trial support is grounded in:
- Rigorous training and qualification of every nurse delivering trial-related care
- Clearly documented delegation and communication pathways back to the investigator
- Point-of-care data capture designed for accuracy, traceability, and audit-readiness
- Proactive risk assessment for every home visit – from environmental suitability to sample handling and IMP administration
- Responsive escalation processes so safety findings reach the site quickly
The Bigger Picture
The direction is clear: decentralized and hybrid trial models are not a temporary adaptation – they are becoming a permanent and expected part of how clinical research is conducted. Regulatory guidance is catching up to the reality that patients, Sponsors, and researchers have already embraced: better trials happen when care meets people where they are.
At WEP Clinical, we see this evolution as an opportunity – for patients to access research more easily, for Sponsors to run more efficient and inclusive trials, and for mobile nursing to be recognized as the skilled, accountable, and essential part of the clinical trial ecosystem that it has always been.
With every patient, wherever they are.
WEP Clinical partners with Sponsors and CROs to deliver compliant, high-quality home-based and decentralized trial support, backed by rigorous training, documentation, and oversight frameworks built for today’s regulatory landscape.
